BR112015001847A8 - Composições e tratamento para doenças e distúrbios nos olhos - Google Patents

Composições e tratamento para doenças e distúrbios nos olhos

Info

Publication number
BR112015001847A8
BR112015001847A8 BR112015001847A BR112015001847A BR112015001847A8 BR 112015001847 A8 BR112015001847 A8 BR 112015001847A8 BR 112015001847 A BR112015001847 A BR 112015001847A BR 112015001847 A BR112015001847 A BR 112015001847A BR 112015001847 A8 BR112015001847 A8 BR 112015001847A8
Authority
BR
Brazil
Prior art keywords
compositions
disorders
treating
treatment
eye diseases
Prior art date
Application number
BR112015001847A
Other languages
English (en)
Other versions
BR112015001847A2 (pt
Inventor
Kenneth Sawyer
Wei-Wei Chang
Original Assignee
Glia Llc
Rhodes Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glia Llc, Rhodes Tech filed Critical Glia Llc
Publication of BR112015001847A2 publication Critical patent/BR112015001847A2/pt
Publication of BR112015001847A8 publication Critical patent/BR112015001847A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Abstract

uso de uma composição para o tratamento da síndrome do olho seco ou ceratoconjuntivite seca em um paciente e uso de uma composição para o tratamento dos síntomas da síndrome do olho seco. a presente invenção refere-se a composições e métodos para tratamento de doenças e distúrbios dos olhos. mais especificamente, a presente invenção provê composições compreendendo progesterona e métodos para tratamento doenças e distúrbios da superfície ocular compreendendo aplicar topicamente tais composições.
BR112015001847A 2012-07-27 2013-07-26 Composições e tratamento para doenças e distúrbios nos olhos BR112015001847A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261676530P 2012-07-27 2012-07-27
US201361756321P 2013-01-24 2013-01-24
PCT/US2013/052264 WO2014018856A1 (en) 2012-07-27 2013-07-26 Compositions and treatment for eye diseases and disorders

Publications (2)

Publication Number Publication Date
BR112015001847A2 BR112015001847A2 (pt) 2017-07-04
BR112015001847A8 true BR112015001847A8 (pt) 2021-09-08

Family

ID=49997851

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015001847A BR112015001847A8 (pt) 2012-07-27 2013-07-26 Composições e tratamento para doenças e distúrbios nos olhos

Country Status (20)

Country Link
US (2) US20150216877A1 (pt)
EP (1) EP2877184B1 (pt)
JP (1) JP6209777B2 (pt)
KR (1) KR102097663B1 (pt)
CN (2) CN107595857A (pt)
AU (1) AU2013295645B2 (pt)
BR (1) BR112015001847A8 (pt)
CA (1) CA2880027C (pt)
DK (1) DK2877184T3 (pt)
ES (1) ES2759781T3 (pt)
HK (1) HK1210968A1 (pt)
HU (1) HUE046963T2 (pt)
IL (1) IL236920B (pt)
IN (1) IN2015DN00542A (pt)
MX (1) MX362185B (pt)
NZ (1) NZ704247A (pt)
PL (1) PL2877184T3 (pt)
PT (1) PT2877184T (pt)
WO (1) WO2014018856A1 (pt)
ZA (1) ZA201500561B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2014239842B2 (en) 2013-03-15 2018-07-19 Glia, Llc Cranial delivery of pharmaceuticals
WO2015080758A1 (en) * 2013-11-27 2015-06-04 Al-Qahtani Ahmed H Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
EP3171872B1 (en) 2014-07-21 2020-11-11 Glia, LLC Method for treating radiotherapy-and-chemotherapy associated cognitive or emotional impairment with cannabinoids
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
KR101960023B1 (ko) * 2016-12-21 2019-03-20 김보경 이산화탄소 발생 장치
US20230091716A1 (en) * 2020-02-12 2023-03-23 Glia, Llc Progesterone Combinations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102656A (en) 1983-07-29 1992-04-07 The Mennen Company Antiperspirant creams
US4937069A (en) 1985-11-15 1990-06-26 Bristol-Myers Squibb Company Anhydrous semi-solid antiperspirant suspension
US5069897A (en) 1987-10-16 1991-12-03 The Proctor & Gamble Company Antiperspirant creams
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
US20080132475A1 (en) 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
WO2009046967A1 (en) * 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
CN101757622A (zh) * 2008-11-28 2010-06-30 天津金耀集团有限公司 一种眼部抗炎的药物组合物
EP2482788B1 (en) * 2009-10-02 2022-12-14 Journey Medical Corporation Topical tetracycline compositions

Also Published As

Publication number Publication date
US9925201B2 (en) 2018-03-27
PT2877184T (pt) 2019-12-02
CN104661663A (zh) 2015-05-27
CA2880027C (en) 2021-12-07
US20170189413A1 (en) 2017-07-06
EP2877184A1 (en) 2015-06-03
EP2877184A4 (en) 2016-03-30
HUE046963T2 (hu) 2020-04-28
HK1210968A1 (en) 2016-05-13
MX2015001250A (es) 2015-10-22
CA2880027A1 (en) 2014-01-30
JP6209777B2 (ja) 2017-10-11
IN2015DN00542A (pt) 2015-06-26
WO2014018856A1 (en) 2014-01-30
CN107595857A (zh) 2018-01-19
IL236920B (en) 2018-06-28
PL2877184T3 (pl) 2020-04-30
ES2759781T3 (es) 2020-05-12
AU2013295645A1 (en) 2015-02-05
US20150216877A1 (en) 2015-08-06
ZA201500561B (en) 2016-04-28
BR112015001847A2 (pt) 2017-07-04
MX362185B (es) 2019-01-08
EP2877184B1 (en) 2019-09-04
JP2015524434A (ja) 2015-08-24
NZ704247A (en) 2018-04-27
KR20150038311A (ko) 2015-04-08
DK2877184T3 (da) 2019-12-09
KR102097663B1 (ko) 2020-04-06
AU2013295645B2 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
BR112015001847A8 (pt) Composições e tratamento para doenças e distúrbios nos olhos
AU2018236800B2 (en) DNA-PK inhibitors
AU2016219611A1 (en) Compositions comprising mixtures of semifluorinated alkanes
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112015019794A2 (pt) composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto
BR112014026703A2 (pt) inibidores de dna-pk
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
WO2018115097A9 (en) Ophthalmic composition for treatment of dry eye disease
BR112016006926A2 (pt) composições compreendendo um conjugado de ácido quínico com ácido cafeico, usos terapêuticos e cosméticos
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112015024846A2 (pt) composições para utilização no estímulo do crescimento ósseo
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
BR112015003729A8 (pt) Composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
BR112017007813A2 (pt) composições oftalmológicas, método de prevenção, redução ou tratamento de transtornos causados por olhos secos e uso de ciclosporina e trealose
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
BR112014030534A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada
BR112017007025A2 (pt) sulfatos de colesterol oxigenados para terapia de distúrbios causados por pelo menos um de atividade de leptina atenuada e um distúrbio de armazenamento de lipídio
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112015001859A2 (pt) tratamento de inflamação utilizando serelaxina
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GLIA, LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]